JP2017519740A - ドラプロイン‐ドライソロイインペプチド誘導体 - Google Patents

ドラプロイン‐ドライソロイインペプチド誘導体 Download PDF

Info

Publication number
JP2017519740A
JP2017519740A JP2016569825A JP2016569825A JP2017519740A JP 2017519740 A JP2017519740 A JP 2017519740A JP 2016569825 A JP2016569825 A JP 2016569825A JP 2016569825 A JP2016569825 A JP 2016569825A JP 2017519740 A JP2017519740 A JP 2017519740A
Authority
JP
Japan
Prior art keywords
methoxy
methyl
methylbutanamide
amino
pyrrolidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016569825A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017519740A5 (https=
Inventor
ブライアン アラン メンデルソーン
ブライアン アラン メンデルソーン
ジュリエン デュガル‐テリア
ジュリエン デュガル‐テリア
スチュアート ダニエル バーンシェア
スチュアート ダニエル バーンシェア
Original Assignee
アジェンシス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アジェンシス，インコーポレイテッド filed Critical アジェンシス，インコーポレイテッド
Publication of JP2017519740A publication Critical patent/JP2017519740A/ja
Publication of JP2017519740A5 publication Critical patent/JP2017519740A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016569825A 2014-05-28 2015-05-27 ドラプロイン‐ドライソロイインペプチド誘導体 Pending JP2017519740A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462004084P 2014-05-28 2014-05-28
US62/004,084 2014-05-28
PCT/US2015/032704 WO2015183978A1 (en) 2014-05-28 2015-05-27 Derivatives of dolaproine-dolaisoleuine peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020081698A Division JP6995160B2 (ja) 2014-05-28 2020-05-07 ドラプロイン‐ドライソロイインペプチド誘導体

Publications (2)

Publication Number Publication Date
JP2017519740A true JP2017519740A (ja) 2017-07-20
JP2017519740A5 JP2017519740A5 (https=) 2018-07-05

Family

ID=54699722

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016569825A Pending JP2017519740A (ja) 2014-05-28 2015-05-27 ドラプロイン‐ドライソロイインペプチド誘導体
JP2020081698A Active JP6995160B2 (ja) 2014-05-28 2020-05-07 ドラプロイン‐ドライソロイインペプチド誘導体
JP2021202579A Active JP7292366B2 (ja) 2014-05-28 2021-12-14 ドラプロイン‐ドライソロイインペプチド誘導体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020081698A Active JP6995160B2 (ja) 2014-05-28 2020-05-07 ドラプロイン‐ドライソロイインペプチド誘導体
JP2021202579A Active JP7292366B2 (ja) 2014-05-28 2021-12-14 ドラプロイン‐ドライソロイインペプチド誘導体

Country Status (9)

Country Link
US (2) US20170190735A1 (https=)
EP (1) EP3149024B9 (https=)
JP (3) JP2017519740A (https=)
KR (1) KR102413079B1 (https=)
CN (1) CN107041139A (https=)
ES (1) ES2883023T3 (https=)
RU (1) RU2747989C2 (https=)
SG (1) SG11201609739UA (https=)
WO (1) WO2015183978A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3149024B9 (en) * 2014-05-28 2021-10-27 Agensys, Inc. Cytotoxic dolaproine-dolaisoleuine peptide derivatives for the treatment of cancer
WO2017058808A1 (en) * 2015-10-02 2017-04-06 Sirenas Llc Anti-cancer compounds and conjugates thereof
EP4321522A1 (en) * 2022-08-12 2024-02-14 Seagen Inc. Cytotoxic compounds and conjugates thereof
AU2024267769A1 (en) * 2023-05-06 2025-10-16 Remegen Co., Ltd. Preparation method for intermediate of auristatin derivative

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003054A1 (fr) * 1991-08-09 1993-02-18 Teikoku Hormone Mfg. Co., Ltd. Nouveau derive de tetrapeptide
WO1995009864A1 (en) * 1993-10-01 1995-04-13 Teikoku Hormone Mfg. Co., Ltd. Novel peptide derivative
JP2004531544A (ja) * 2001-04-30 2004-10-14 シアトル ジェネティクス，インコーポレーテッド ペンタペプチド化合物及びそれに関する使用
JP2014512375A (ja) * 2011-04-21 2014-05-22 シアトル ジェネティックス， インコーポレイテッド 新規な結合剤−薬物複合体（ａｄｃ）およびそれらの使用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569834B1 (en) 1992-12-03 2003-05-27 George R. Pettit Elucidation and synthesis of antineoplastic tetrapeptide w-aminoalkyl-amides
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
JPH06234790A (ja) * 1993-02-09 1994-08-23 Teikoku Hormone Mfg Co Ltd 新規テトラペプチドアミド誘導体
US5521284A (en) * 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US6323315B1 (en) * 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
ATE459364T1 (de) 2003-10-22 2010-03-15 Univ Johns Hopkins Verbesserte bakteriolyse-kombinationstherapie für die behandlung von tumoren
KR20070050918A (ko) * 2004-07-02 2007-05-16 뉴텍 파마 피엘씨 암의 치료
WO2006132670A2 (en) 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
CN101242816B (zh) * 2005-06-30 2012-10-31 维罗贝股份有限公司 Hcv抑制剂
US7608592B2 (en) 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
JP5171621B2 (ja) * 2005-07-07 2013-03-27 シアトル ジェネティックス， インコーポレイテッド フェニルアラニン側鎖修飾をｃ末端に有するモノメチルバリン化合物
CN106986926A (zh) 2008-01-30 2017-07-28 皮里斯股份公司 具有对人c‑met受体酪氨酸激酶的亲和性的泪脂质运载蛋白的突变蛋白及其获得方法
EP2265283B1 (en) * 2008-03-18 2014-09-03 Seattle Genetics, Inc. Auristatin drug linker conjugates
EP2276509B1 (en) 2008-04-11 2016-06-15 Seattle Genetics, Inc. Detection and tratment of pancreatic, ovarian and other cancers
RU2566693C2 (ru) * 2011-07-08 2015-10-27 Сименс Акциенгезелльшафт Система слоев с двухслойным металлическим слоем
US20130190248A1 (en) * 2011-07-26 2013-07-25 Agensys, Inc. Substituted peptide analogs
MY168297A (en) 2011-11-17 2018-10-23 Pfizer Cytotoxic Peptides and Antibody Drug Conjugates Thereof
US9981046B2 (en) * 2012-05-15 2018-05-29 Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. Drug-conjugates, conjugation methods, and uses thereof
HK1214282A1 (zh) * 2012-11-07 2016-07-22 辉瑞公司 抗-notch3抗体及抗体-药物缀合物
CN104936621A (zh) 2012-11-07 2015-09-23 辉瑞公司 抗IL-13受体α2抗体和抗体-药物缀合物
EP3149024B9 (en) * 2014-05-28 2021-10-27 Agensys, Inc. Cytotoxic dolaproine-dolaisoleuine peptide derivatives for the treatment of cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003054A1 (fr) * 1991-08-09 1993-02-18 Teikoku Hormone Mfg. Co., Ltd. Nouveau derive de tetrapeptide
WO1995009864A1 (en) * 1993-10-01 1995-04-13 Teikoku Hormone Mfg. Co., Ltd. Novel peptide derivative
JP2004531544A (ja) * 2001-04-30 2004-10-14 シアトル ジェネティクス，インコーポレーテッド ペンタペプチド化合物及びそれに関する使用
JP2014512375A (ja) * 2011-04-21 2014-05-22 シアトル ジェネティックス， インコーポレイテッド 新規な結合剤−薬物複合体（ａｄｃ）およびそれらの使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MIYAZAKI ET AL., CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 1995, Vol.43, No.10, JPN6019015654, pages 1706 - 1718, ISSN: 0004026095 *

Also Published As

Publication number Publication date
KR102413079B1 (ko) 2022-06-24
RU2747989C2 (ru) 2021-05-18
WO2015183978A1 (en) 2015-12-03
EP3149024A1 (en) 2017-04-05
JP7292366B2 (ja) 2023-06-16
JP2022027896A (ja) 2022-02-14
US20220204557A1 (en) 2022-06-30
EP3149024B9 (en) 2021-10-27
US20200325170A1 (en) 2020-10-15
CN107041139A (zh) 2017-08-11
JP2020128405A (ja) 2020-08-27
RU2016150426A3 (https=) 2018-12-20
JP6995160B2 (ja) 2022-01-14
US20170190735A1 (en) 2017-07-06
US11312748B2 (en) 2022-04-26
KR20170005495A (ko) 2017-01-13
ES2883023T3 (es) 2021-12-03
RU2016150426A (ru) 2018-07-03
EP3149024A4 (en) 2018-06-06
EP3149024B1 (en) 2021-05-12
SG11201609739UA (en) 2016-12-29

Similar Documents

Publication Publication Date Title
JP7292366B2 (ja) ドラプロイン‐ドライソロイインペプチド誘導体
US20230109312A1 (en) Novel linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
CN107087411A (zh) 鞭毛蛋白组合物及用途
AU2004240248A1 (en) Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13
US11046739B2 (en) BH4 stabilized peptides and uses thereof
BRPI0213223B1 (pt) Polipeptídeo, dímero ou multímero, polinucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica, e, uso de uma composição
MX2011004019A (es) Conjugados de etoposido y doxorubicina para entrega de farmacos.
KR102436012B1 (ko) 항암제 프로드러그 컨쥬게이트의 새로운 용도
TW202116356A (zh) 作為治療劑之微管靶向藥劑之肽結合物
WO2020230780A1 (ja) Ｒａｓ阻害ペプチド
CN108084249A (zh) 一种用于抗雌激素受体α的稳定多肽及其用途
US20010053371A1 (en) Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13
JP2023544223A (ja) 標的化ｐｅｔ／ｓｐｅｃｔ撮像のための放射性標識リガンド及びそれらの使用方法
WO2025116046A1 (ja) ペプチド及び当該ペプチドを含むコンジュゲート
CN111511917B (zh) 肽结合物
JP7714161B2 (ja) クロロトキシン誘導体およびその使用
HK1243085A1 (en) Derivatives of dolaproine-dolaisoleuine peptides
CN109439637B (zh) 一种基于人钙调蛋白磷酸酶b亚基的靶向肽、制备方法及其应用
HK40109540A (zh) 反式环辛烯缀合物
HK40108922A (zh) 用於有效载荷的体内靶向递送的四嗪缀合物
CN121949442A (zh) 海兔脯氨酸-海兔异亮氨酸肽的衍生物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180525

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190802

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200108